Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16903353 | 0.94 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3529765 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3788614 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3614635 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| 4-Fluoro-Piperidinium SCHEMBL4717910 | 0.91 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL618472 | 0.89 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL14992459 | 0.89 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3898493 | 0.89 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL716107 | 0.88 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL77639 | 0.88 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4038060-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115279370-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2021064590-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7671073-B2 | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-1756106-A4 | CYCLOHEXYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060111336-A1 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-05-25 | — | — | US | disclosed |
| CN-1735605-A | Phenylalanine derivative is used for the treatment of or prevent diabetes as depeptidyl peptidase inhibitors | MERCK & CO INC (US) | 2006-02-15 | — | — | CN | disclosed |
| WO-2005116029-A1 | CYCLOHEXYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005108382-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | disclosed |
| EP-1578414-A2 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1562925-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004050022-A2 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004043940-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | SMN1; SMN2 3791/4885NPC1 1410/4885RAB9A 4416/4885 |
| US-20060111336-A1 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | SMN1; SMN2 3767/4885NPC1 1498/4885RAB9A 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.